[144] Athira Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

Athira Pharma, Inc. (ATHA) has filed a Form 144 indicating the planned sale of 8,526 common shares through broker Morgan Stanley Smith Barney LLC. The proposed transaction represents approximately 0.022 % of the company’s 39.0 million shares outstanding and carries an aggregate market value of $2,502 based on the price at the time of filing. The shares originate from a restricted-stock lapse dated 30 June 2025 and are scheduled to be sold on or after 1 July 2025 on the NASDAQ exchange. No previous insider sales were reported during the last three months, and the filer asserts the standard representation of having no undisclosed adverse information about the company.

The notice is procedural, providing investors with transparency into a forthcoming, modest-size insider disposition. Given the small fraction of total shares and the absence of other material operational or financial disclosures, the filing is unlikely to have a meaningful impact on ATHA’s share price or fundamentals.

Insights

Financial Analyst

TL;DR: Minor insider sale of 8.5k ATHA shares (<0.03 % of float); negligible market impact expected.

The Form 144 discloses that an insider intends to sell 8,526 common shares, valued at roughly $2.5 k, via Morgan Stanley. With 39 million shares outstanding, the planned sale is immaterial from a liquidity or signaling standpoint. No pattern of recent selling and no adverse business information are indicated. Investors typically monitor Form 144s for sentiment clues, but this transaction’s size suggests a routine liquidity event following the vesting of restricted stock rather than a bearish outlook. I therefore view the filing as neutral for valuation and trading purposes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Fl. New York NY 10004	8526	2502	39042445	07/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/30/2025	Restricted Stock Lapse - See Remarks	Athira Pharma, Inc.			36666	07/01/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Athira Pharma (ATHA) shares are being sold under this Form 144?

The notice covers 8,526 common shares of Athira Pharma.

What percentage of ATHA’s outstanding shares does the 8,526-share sale represent?

It equals roughly 0.022 % of the 39,042,445 shares outstanding.

When is the approximate sale date for the ATHA shares?

The filer listed 01 July 2025 as the anticipated sale date.

What was the source of the shares being sold?

They were acquired via a restricted stock lapse on 30 June 2025 as part of equity compensation.

Which broker will execute the ATHA share sale?

The broker of record is Morgan Stanley Smith Barney LLC.